2023 年 10 月至 2024 年 1 月，VEBIS 医院网络，欧洲，针对目标接种人群的 COVID-19 XBB.1.5 疫苗对成人住院的早期有效性。
Early COVID-19 XBB.1.5 Vaccine Effectiveness Against Hospitalisation Among Adults Targeted for Vaccination, VEBIS Hospital Network, Europe, October 2023-January 2024.
机构信息
Epidemiology Department, Epiconcept, Paris, France.
National Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
出版信息
Influenza Other Respir Viruses. 2024 Aug;18(8):e13360. doi: 10.1111/irv.13360.
We conducted a multicentre test-negative case-control study covering the period from October 2023 to January 2024 among adult patients aged ≥ 18 years hospitalised with severe acute respiratory infection in Europe. We provide early estimates of the effectiveness of the newly adapted XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation. Vaccine effectiveness was 49% overall, ranging between 69% at 14-29 days and 40% at 60-105 days post vaccination. The adapted XBB.1.5 COVID-19 vaccines conferred protection against COVID-19 hospitalisation in the first 3.5 months post vaccination, with VE > 70% in older adults (≥ 65 years) up to 1 month post vaccination.
我们开展了一项多中心病例对照研究，覆盖 2023 年 10 月至 2024 年 1 月期间，在欧洲≥18 岁因严重急性呼吸道感染住院的成年患者。我们提供了新适应的 XBB.1.5 COVID-19 疫苗对 PCR 确诊的 SARS-CoV-2 住院的早期有效性估计。总体疫苗有效性为 49%，在接种后 14-29 天为 69%，在 60-105 天为 40%。新适应的 XBB.1.5 COVID-19 疫苗在接种后 3.5 个月内对 COVID-19 住院提供了保护，在接种后 1 个月内对≥65 岁的老年人的疫苗有效性>70%。
Zotero 插件